AGENUS INC (AGEN) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income $11.29M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income $15.05M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$4.54M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$16.71M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | $11.29M | (m) | $34.52M | (m) | $0.00* | -$31.20M* | (m) | $14.76M | (m) | (m) |
| 2026-03-31 | Reported | (m) | $15.05M | (m) | $33.74M | (m) | $0.00 | -$35.95M | (m) | $11.82M | (m) | (m) |
| 2025-09-30 | Reported | (m) | -$4.54M | (m) | $30.23M | (m) | $0.00* | -$14.74M* | (m) | $23.60M | (m) | (m) |
| 2025-06-30 | Reported | (m) | -$16.71M | (m) | $25.69M | (m) | $1.00K* | -$20.22M* | (m) | $26.71M | (m) | (m) |
| 2025-03-31 | Reported | (m) | -$13.31M | (m) | $24.07M | (m) | $5.00K | -$25.62M | (m) | $21.52M | (m) | (m) |
| 2024-09-30 | Reported | (m) | -$31.50M | (m) | $25.11M | (m) | $7.00K* | -$53.29M* | (m) | $41.06M | (m) | (m) |
| 2024-06-30 | Reported | (m) | -$30.19M | (m) | $23.51M | (m) | $461.00K* | -$38.18M* | (m) | $36.77M | (m) | (m) |
| 2024-03-31 | Reported | (m) | -$32.88M | (m) | $28.00M | (m) | $35.00K | -$38.19M | (m) | $43.92M | (m) | (m) |
| 2023-09-30 | Reported | (m) | -$46.34M | (m) | $24.31M | (m) | $3.45M* | -$65.23M* | (m) | $51.44M | (m) | (m) |
| 2023-06-30 | Reported | (m) | -$54.67M | (m) | $25.30M | (m) | $4.44M* | -$60.04M* | (m) | $59.28M | (m) | (m) |
| 2023-03-31 | Reported | (m) | -$54.34M | (m) | $22.90M | (m) | $1.84M | -$58.53M | (m) | $57.12M | (m) | (m) |
| 2022-09-30 | Reported | (m) | -$41.65M | (m) | $22.77M | (m) | $15.72M* | -$32.19M* | (m) | $46.01M | (m) | (m) |
| 2022-06-30 | Reported | (m) | -$44.56M | (m) | $20.93M | (m) | $18.45M* | -$43.45M* | (m) | $44.96M | (m) | (m) |
| 2022-03-31 | Reported | (m) | -$35.46M | (m) | $25.94M | (m) | $4.54M | -$52.39M | (m) | $42.44M | (m) | (m) |
| 2021-09-30 | Reported | (m) | $187.54M | (m) | $252.95M | (m) | $22.39M* | $131.37M* | (m) | $42.94M | (m) | (m) |
| 2021-06-30 | Reported | (m) | -$66.39M | (m) | $10.73M | (m) | $2.27M* | -$55.56M* | (m) | $45.51M | (m) | (m) |
| 2021-03-31 | Reported | (m) | -$41.37M | (m) | $11.72M | (m) | $196.00K | -$42.74M | (m) | $36.68M | (m) | (m) |
| 2020-09-30 | Reported | (m) | -$34.79M | (m) | $14.83M | (m) | $870.00K* | -$31.63M* | (m) | $32.13M | (m) | (m) |
| 2020-06-30 | Reported | (m) | -$33.27M | (m) | $26.95M | (m) | $1.12M* | -$37.38M* | (m) | $38.55M | (m) | (m) |
| 2020-03-31 | Reported | (m) | -$27.46M | (m) | $15.13M | (m) | $644.00K | -$34.51M | (m) | $36.36M | (m) | (m) |
| 2019-09-30 | Reported | (m) | -$35.92M | (m) | $19.94M | (m) | $839.00K* | -$27.79M* | (m) | $46.13M | (m) | (m) |
| 2019-06-30 | Reported | (m) | -$41.15M | (m) | $15.71M | (m) | $1.26M* | $40.90M | (m) | $45.24M | (m) | (m) |
| 2019-03-31 | Reported | (m) | $26.21M | (m) | $79.89M | (m) | $1.50M | $76.59M | (m) | $40.13M | (m) | (m) |
| 2018-09-30 | Reported | (m) | -$26.07M | (m) | $12.80M | (m) | $820.00K* | -$24.60M | (m) | $29.85M | (m) | (m) |
| 2018-06-30 | Reported | (m) | -$16.57M | (m) | $15.89M | (m) | $681.00K* | -$30.50M | (m) | $29.27M | (m) | (m) |
| 2018-03-31 | Reported | (m) | -$41.75M | (m) | $1.64M | (m) | $1.50M | -$40.25M | (m) | $29.44M | (m) | (m) |
| 2017-09-30 | Reported | (m) | -$31.66M | (m) | $3.36M | (m) | $960.50K* | -$26.15M* | (m) | $25.79M | (m) | (m) |
| 2017-06-30 | Reported | (m) | -$28.89M | (m) | $4.21M | (m) | $988.93K* | (m) | (m) | $25.82M | (m) | (m) |
| 2017-03-31 | Reported | (m) | -$13.26M | (m) | $26.96M | (m) | $417.00K | (m) | (m) | $32.64M | (m) | (m) |
| 2016-09-30 | Reported | (m) | -$36.22M | (m) | (m) | (m) | $5.03M* | (m) | (m) | $21.59M | (m) | (m) |
| 2016-06-30 | Reported | (m) | -$23.61M | (m) | (m) | (m) | $1.63M* | (m) | (m) | $22.36M | (m) | (m) |
| 2016-03-31 | Reported | (m) | -$27.97M | (m) | (m) | (m) | $1.54M | (m) | (m) | $25.04M | (m) | (m) |
| 2015-09-30 | Reported | (m) | -$11.07M | (m) | (m) | (m) | $1.29M* | (m) | (m) | $18.50M | (m) | (m) |
| 2015-06-30 | Reported | (m) | -$33.20M | (m) | (m) | (m) | $1.20M* | -$12.87M* | (m) | $24.77M | (m) | (m) |
| 2015-03-31 | Reported | (m) | -$18.29M | (m) | (m) | (m) | $323.55K | $3.30M | (m) | $9.22M | (m) | (m) |
| 2014-09-30 | Reported | (m) | -$7.67M | (m) | (m) | (m) | $334.38K* | -$8.11M* | (m) | $5.28M | (m) | (m) |
| 2014-06-30 | Reported | (m) | -$8.50M | (m) | (m) | (m) | $598.50K* | -$9.50M* | (m) | $5.22M | (m) | (m) |
| 2014-03-31 | Reported | (m) | -$9.82M | (m) | (m) | (m) | $172.59K | -$10.12M | (m) | $4.47M | (m) | (m) |
| 2013-09-30 | Reported | (m) | -$6.81M | (m) | (m) | (m) | $155.62K* | -$4.43M* | (m) | $3.89M | (m) | (m) |
| 2013-06-30 | Reported | (m) | -$7.33M | (m) | (m) | (m) | $214.06K* | -$5.66M* | (m) | $3.32M | (m) | (m) |
| 2013-03-31 | Reported | (m) | -$4.61M | (m) | (m) | (m) | $377.32K | -$3.90M | (m) | $2.55M | (m) | (m) |
| 2012-09-30 | Reported | (m) | -$4.54M | (m) | (m) | (m) | -$36.03K* | -$3.64M* | (m) | -$2.61M | (m) | (m) |
| 2012-06-30 | Reported | (m) | -$5.77M | (m) | (m) | (m) | -$65.02K* | -$3.35M* | (m) | -$2.91M | (m) | (m) |
| 2012-03-31 | Reported | (m) | $7.80M | (m) | (m) | (m) | $0.00 | $11.27M | (m) | -$2.68M | (m) | (m) |
| 2011-09-30 | Reported | (m) | -$4.44M | (m) | (m) | (m) | $4.68K* | -$3.40M* | (m) | $2.53M | (m) | (m) |
| 2011-06-30 | Reported | (m) | -$4.70M | (m) | (m) | (m) | $6.41K* | -$4.03M* | (m) | $2.82M | (m) | (m) |
| 2011-03-31 | Reported | (m) | -$5.02M | (m) | (m) | (m) | $43.46K | -$4.64M | (m) | $2.82M | (m) | (m) |
| 2010-09-30 | Reported | (m) | -$4.89M | (m) | (m) | (m) | $45.90K* | -$4.14M* | (m) | $2.82M | (m) | (m) |
| 2010-06-30 | Reported | (m) | -$4.65M | (m) | (m) | (m) | (m) | (m) | (m) | $2.63M | (m) | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$20.17M | (m) | $114.20M | (m) | $6.00K | -$77.19M | (m) | $79.34M | (m) | $0.00 |
| 2024-12-31 | Reported | (m) | -$120.47M | (m) | $103.46M | (m) | $576.00K | -$158.31M | (m) | $155.53M | (m) | $0.00 |
| 2023-12-31 | Reported | (m) | -$159.55M | (m) | $156.31M | (m) | $9.95M | -$224.20M | (m) | $234.57M | (m) | $0.00 |
| 2022-12-31 | Reported | (m) | -$179.43M | (m) | $98.02M | (m) | $53.06M | -$175.37M | (m) | $186.69M | (m) | $0.00 |
| 2021-12-31 | Reported | (m) | $25.75M | (m) | $295.67M | (m) | $33.81M | $10.14M | (m) | $178.61M | (m) | $0.00 |
| 2020-12-31 | Reported | (m) | -$117.23M | (m) | $88.17M | (m) | $3.47M | -$139.10M | (m) | $142.62M | (m) | $0.00 |
| 2019-12-31 | Reported | (m) | -$70.14M | (m) | $150.05M | (m) | $4.66M | -$18.68M | (m) | $168.34M | (m) | $0.00 |
| 2018-12-31 | Reported | (m) | -$123.82M | (m) | $36.78M | (m) | $3.60M | -$131.09M | (m) | $124.60M | (m) | $0.00 |
| 2017-12-31 | Reported | (m) | -$103.80M | (m) | $42.88M | (m) | $3.12M | -$94.23M | (m) | $116.13M | (m) | $0.00 |
| 2016-12-31 | Reported | (m) | -$107.48M | (m) | $22.57M | (m) | $12.52M | -$79.96M | (m) | $94.97M | (m) | $0.00 |
| 2015-12-31 | Reported | (m) | -$80.70M | (m) | (m) | (m) | $3.59M | (m) | (m) | $70.44M | (m) | -$5.39M |
| 2014-12-31 | Reported | (m) | -$43.32M | (m) | (m) | (m) | $2.82M | -$38.23M | (m) | $22.35M | (m) | $0.00 |
| 2013-12-31 | Reported | (m) | -$24.98M | (m) | (m) | (m) | $813.52K | -$19.53M | (m) | $13.01M | (m) | $0.00 |
| 2012-12-31 | Reported | (m) | -$6.74M | (m) | (m) | (m) | $103.44K | $1.01M | (m) | $10.56M | (m) | $0.00 |
| 2011-12-31 | Reported | (m) | -$19.09M | (m) | (m) | (m) | $54.55K | -$16.25M | (m) | $11.02M | (m) | $0.00 |
| 2010-12-31 | Reported | (m) | -$21.75M | (m) | (m) | (m) | $130.44K | -$14.76M | (m) | $12.88M | (m) | (m) |
| 2009-12-31 | Reported | (m) | -$27.68M | (m) | (m) | (m) | $243.87K | -$24.19M | (m) | $16.90M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |